logo
Plus   Neg
Share
Email

Alkermes Announces NDA Filing Acceptance For Diroximel Fumarate - Quick Facts

Alkermes plc (ALKS) and Biogen Inc. (BIIB) announced the U.S. FDA has accepted for review the New Drug Application for diroximel fumarate (BIIB098), an oral fumarate in development for the treatment of relapsing forms of multiple sclerosis. The NDA has been assigned a PDUFA target action date in the fourth quarter of 2019.

Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway, referencing Biogen's dimethyl fumarate data. If approved, Biogen intends to market diroximel fumarate under the brand name, VUMERITY.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
RELATED NEWS
Follow RTT